At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sildenafil for Treatment of Choroidal Ischemia
In Brief
A Phase 2 clinical trial evaluating Sildenafil, Standard of Care Sildenafil, and 2 other interventions for Choroidal Ischemia and 4 related conditions. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The hypothesis of this study is to determine if there is a benefit afforded by the use of systemic Sildenafil to patients with choroidal and retinal degenerations and dystrophies, such as vitelliform degeneration, dry and reticular age-related macular degeneration (AMD) as well as patients with hereditary and acquired retinal dystrophies such as retinitis pigmentosa and central serous retinopathy.
Study Details
Timeline
Interventions
Initial Sildenafil dosage will be weight dependent. Participants will start at 40 mg daily (20mg in the morning, 20 mg in the evening) or 60 mg daily (40mg in the morning and 20 mg in the evening). Sildenafil dosage may be increased to up to 80mg daily (20-40mg in the morning and 20-40mg in the evening) based on the response to lower doses. If the participant has not had improvement after initial treatment, the dose may be increased, at the discretion of the study physician.
Medical record review of participants that receive Sildenafil as part of standard of care.
Retinal photographs will be taken at each study visit.
Visual acuity will be measured with Snellen Eye Chart at each study visit.